Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.4
4.5
Journals
Microorganisms
Special Issues
The Phage: Biology and Therapeutic Use
share announcement

Special Issue "The Phage: Biology and Therapeutic Use"

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Molecular Microbiology and Immunology".

Deadline for manuscript submissions: 15 December 2023 | Viewed by 2233

Special Issue Editors

Prof. Dr. Richard James
E-Mail Website
Guest Editor
School of Life Sciences, University of Nottingham, Nottingham, UK
Interests: phage therapy
Dr. David R. Harper

E-Mail Website
Guest Editor
Evolution Biotechnologies, Sharnbrook, UK
Interests: phage therapy; biological control

Special Issue Information

Dear Colleagues,

Phage therapy -  the use of bacteriophages as specific antibacterial therapeutic agents – has been around for over a hundred years. In that time it has been seen as everything from an almost miraculous cure to a failed alternative to “real” medicine. In recent years, based on a far more complete understanding of bacteriophage biology, opinion has swung once again and bacteriophages are seen once more as a viable approach to the very real crisis of antibiotic resistance. As it has been for some time, the key is obtaining hard, verifiable clinical data.

This special edition of “Microorganisms”, entitled "The Phage: Biology and Therapeutic Use" is intended to contain both reviews and original articles focussed on the emerging data in the field, and on supporting the viability of this approach in an area with real unmet need. With invited articles contributed by experts from around the world, it is intended to form a valuable resource for both workers in the field and curious newcomers to the sometimes abstruse field of bacteriophages, their biology, and the emerging potential for their therapeutic use.

Prof. Dr. Richard James
Dr. David R. Harper
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bacteriophage
  • phage therapy
  • antibiotic resistance
  • novel antibiotics
  • clinical trials

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

get_app
Communication
Peptidoglycan Endopeptidase from Novel Adaiavirus Bacteriophage Lyses Pseudomonas aeruginosa Strains as Well as Arthrobacter globiformis and A. pascens Bacteria
by
Karel Petrzik
Microorganisms 2023, 11(8), 1888; https://doi.org/10.3390/microorganisms11081888 - 26 Jul 2023
Viewed by 380
Abstract
A novel virus lytic for Pseudomonas aeruginosa has been purified. Its viral particles have a siphoviral morphology with a head 60 nm in diameter and a noncontractile tail 184 nm long. The dsDNA genome consists of 16,449 bp, has cohesive 3′ termini, and [...] Read more.
A novel virus lytic for Pseudomonas aeruginosa has been purified. Its viral particles have a siphoviral morphology with a head 60 nm in diameter and a noncontractile tail 184 nm long. The dsDNA genome consists of 16,449 bp, has cohesive 3′ termini, and encodes 28 putative proteins in a single strain. The peptidoglycan endopeptidase encoded by ORF 16 was found to be the lytic enzyme of this virus. The recombinant, purified enzyme was active up to 55 °C in the pH range 6–9 against all tested isolates of P. aeruginosa, but, surprisingly, also against the distant Gram-positive micrococci Arthrobacter globiformis and A. pascens. Both this virus and its endolysin are further candidates for possible treatment against P. aeruginosa and probably also other bacteria. Full article
(This article belongs to the Special Issue The Phage: Biology and Therapeutic Use)
►▼ Show Figures

Figure 1

Review

Jump to: Research

get_app
Review
The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era
by
Su Jin Jo
,
Jun Kwon
,
Sang Guen Kim
and
Seung-Jun Lee
Microorganisms 2023, 11(9), 2311; https://doi.org/10.3390/microorganisms11092311 - 13 Sep 2023
Viewed by 330
Abstract
Amid the escalating challenges of antibiotic resistance, bacterial infections have emerged as a global threat. Bacteriophages (phages), viral entities capable of selectively infecting bacteria, are gaining momentum as promising alternatives to traditional antibiotics. Their distinctive attributes, including host specificity, inherent self-amplification, and potential [...] Read more.
Amid the escalating challenges of antibiotic resistance, bacterial infections have emerged as a global threat. Bacteriophages (phages), viral entities capable of selectively infecting bacteria, are gaining momentum as promising alternatives to traditional antibiotics. Their distinctive attributes, including host specificity, inherent self-amplification, and potential synergy with antibiotics, render them compelling candidates. Phage engineering, a burgeoning discipline, involves the strategic modification of bacteriophages to enhance their therapeutic potential and broaden their applications. The integration of CRISPR-Cas systems facilitates precise genetic modifications, enabling phages to serve as carriers of functional genes/proteins, thereby enhancing diagnostics, drug delivery, and therapy. Phage engineering holds promise in transforming precision medicine, addressing antibiotic resistance, and advancing diverse applications. Emphasizing the profound therapeutic potential of phages, this review underscores their pivotal role in combatting bacterial diseases and highlights their significance in the post-antibiotic era. Full article
(This article belongs to the Special Issue The Phage: Biology and Therapeutic Use)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop